June 17, 2008:     Ipca - Ranbaxy Alliance receives U.S. FDA Marketing Approval for Metoclopramide Tablets.

Ipca Laboratories Ltd. (Ipca) had earlier announced strategic alliance with Ranbaxy Pharmaceuticals Inc. (Ranbaxy) based in Jacksonville, Florida (USA), a wholly owned subsidiary of Ranbaxy Laboratories Ltd. (RLL), India's largest pharmaceutical company. 

Under the strategic alliance, Ipca has now received approval from U.S. Food and Drugs Administration to manufacture and market Metoclopramide Tablets USP 5mg and 10mg in the US market. Total annual market sales for Metoclopramide tablets in U.S. were US $ 27 millions (IMS-MAT: March 2008). This is the sixth such product approval received under the alliance from U.S. FDA.

Ipca will manufacture and Ranbaxy will market this formulation in the US healthcare system using Ipca's DMF approved Active Pharmaceutical ingredient (API) - Metoclopramide. Ranbaxy will commercialise this product in the U.S. market utilizing its established marketing expertise and distribution network.

Ipca is a fully integrated pharmaceutical Company engaged in the manufacturing and marketing of a range of pharmaceuticals world over. Ipca's exports to over 110 countries across the globe contributed about 50% of the Company's income of Rs.1085 crores in the financial year 2007-08.

Premchand Godha
Managing Director

Back